Based on the Vaccine Adverse Event Reporting System, this article reports on the prevalence of presumptive Guillain-Barré syndrome among recipients of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine.
Source: JAMA Online First
| Curriculum Vitae | Résumé |
Based on the Vaccine Adverse Event Reporting System, this article reports on the prevalence of presumptive Guillain-Barré syndrome among recipients of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine.
Source: JAMA Online First